Ageing and Dementia (eBook, PDF)

Current and Future Concepts
Redaktion: Jellinger, Kurt; Windisch, Manfred; Schmidt, Reinhold

• Format: PDF

Produktbeschreibung

Epidemiological studies, modern clinical, neuroimaging, neuropsychological, molecular biological, and genetic studies have considerably enhanced our knowledge about ageing processes of the human brain, its sequelae, diagnostic, and therapeutic possibilities and limits. In addition to Alzheimer's disease and other degenerative dementias, the impact of cerebrovascular lesions and their risk factors in the pathogenesis of cognitive disorders of the aged are increasingly acknowledged, and the recognition of mild cognitive impairment as a frequent initial stage of developing dementia is becoming an increasingly important diagnostic and therapeutic problem. The included papers were presented at the 7th International Symposium in Graz, Sept. 2001 and give a timely overview of the current and future concepts of pathogenesis, diagnosis, and treatment strategies of pathological brain ageing and dementias, early recognition of mild cognitive impairment and future possiblities of prevention of dementing processes.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Springer Vienna
• Seitenzahl: 384
• Erscheinungstermin: 28. Juni 2011
• Englisch
• ISBN-13: 9783709161395
• Artikelnr.: 53391681

Inhaltsangabe

Anti-oxidants and cognitive function: a review of clinical and epidemiologic studies.- Brain abnormalities in the elderly: frequency and predictors in the United States (the Cardiovascular Health Study).- Apolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam study.- The spectrum of age-associated brain abnormalities: their measurement and histopathological correlates.- Cognitive correlates of cerebral white matter changes.- Concepts on the prognostic significance of white matter changes.- Difficulties in the clinical diagnosis of vascular dementia and dementia of the Alzheimer type - comparison of clinical classifications.- Problems of differential diagnosis between depressive pseudo- dementia and Alzheimer's disease.- The neuropathological diagnosis of Alzheimer disease.- The progression of the lesions in Alzheimer disease: insights from a prospective clinico- pathological study.- Evolution of neuronal changes in the course of Alzheimer's disease.- The cytoskeleton in Alzheimer disease.- Mechanisms of synaptic pathology in Alzheimer's disease.- Proteolytic processing of Alzheimer's disease associated proteins.- Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles.- Presenilins and Alzheimer's disease: the role of A?42.- Biological markers for the diagnosis of Alz- heimer's disease.- Apolipoprotein E4, cholinergic integrity and the pharmaco- genetics of Alzheimer's disease.- Cerebrospinal fluid levels of A?42 and tau: potential markers of Alzheimer's disease.- Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing.- Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia.- Current diagnostic methods andoutcome variables for clinical investigation of Alzheimer's disease.- Perspectives in clinical Alzheimer's disease research and the development of antidementia drugs.- The role of glutamate in dementia.- Neurotrophic activities and therapeutic experience with a brain-derived peptide preparation.- Brain-derived peptides reduce the size of cerebral infarction and loss of MAP2 immunoreactivity after focal ischemia in rats.- The influence of Cerebrolysin® and E021 on spatial navigation of 24-month-old rats.- Molecular regulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived factors.- Antioxidant systemic effect of short-term Cerebrolysin® administration.- Can Cerebrolysin® influence chronic deterioration of spatial learning and memory?.- Cerebrolysin® protects isolated cortical neurons from neurodegeneration after brief histotoxic hypoxia.- Further evidence that Cerebrolysin® protects cortical neurons from neurodegeneration in vitro.- Influence of BDNF and FCS on viability and programmed cell death (PCD) of developing cortical chicken neurons in vitro.- Dose-dependent effects of Cerebrolysin® on EEG and short term memory of healthy volunteers during control and hyperventilation induced cerebral ischemia.